In fact, either the CAMK2 or CREB1 inhibitor resensitizes doxorubicin-resistant ovarian cancer cells, showing that the CAMK2/CREB1 pathway is a suitable target pathway for future therapeutic development. Here, CREB1 is linked to ovarian carcinoma.